Clinical-stage biotechnology company developing cell therapies for degenerative diseases.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to pioneering novel cell therapies aimed at treating degenerative diseases globally. Specializing in advanced medical solutions, Lineage focuses on developing transformative treatments that address critical unmet needs across various therapeutic areas.
Among its pioneering initiatives, Lineage is advancing OpRegen, a cutting-edge retinal pigment epithelium cell replacement therapy currently undergoing Phase I/IIa clinical trials. OpRegen holds promise for treating dry age-related macular degeneration, a significant advancement in the field of ophthalmology.
Additionally, Lineage's portfolio includes OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa multicenter clinical trials. OPC1 targets acute spinal cord injuries, aiming to restore neurological function and improve patient outcomes. The company also develops VAC2, an innovative allogeneic cancer immunotherapy using antigen-presenting dendritic cells, currently undergoing Phase I clinical trials for non-small cell lung cancer.
Beyond these therapeutic breakthroughs, Lineage Cell Therapeutics is actively involved in researching and developing treatments for retinal diseases, neurological disorders, and oncology. Established in 1990 as BioTime, Inc., and rebranded as Lineage Cell Therapeutics, Inc. in August 2019, the company is headquartered in Carlsbad, California. With a commitment to scientific excellence and patient-centric innovation, Lineage continues to push the boundaries of cellular therapy, striving to transform the landscape of medical care worldwide.